NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 39,816 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 39,816 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $32.62, for a total value of $1,298,797.92. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at $794,394.86. This trade represents a 62.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, January 28th, Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $31.80, for a total transaction of $1,037,061.60.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $32.78, for a total transaction of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.75, for a total transaction of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock opened at $31.44 on Friday. The stock’s fifty day moving average price is $35.20 and its 200 day moving average price is $31.25. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00. The company has a market cap of $3.56 billion, a price-to-earnings ratio of -15.34 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. As a group, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

NAMS has been the subject of several research reports. Royal Bank Of Canada lifted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Stifel Nicolaus lifted their price target on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Needham & Company LLC increased their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Finally, Leerink Partners reiterated an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $47.00.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently modified their holdings of NAMS. Jennison Associates LLC increased its holdings in NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after buying an additional 1,252,451 shares in the last quarter. Knights of Columbus Asset Advisors LLC acquired a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at about $595,000. Franklin Resources Inc. grew its position in shares of NewAmsterdam Pharma by 30.6% during the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after acquiring an additional 78,300 shares during the period. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares in the last quarter. Finally, Maverick Capital Ltd. raised its holdings in NewAmsterdam Pharma by 178.8% in the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after purchasing an additional 982,405 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.